Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia

NCT00270478 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease
Chronic Kidney Disease
Pulmonary Hypertension

Interventions

DRUG: Erythropoietin and Hydroxyurea

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)